Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.69 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.69 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 9/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13116861 | 0.92 | CDK2 (0.66) | CDK2CCNA2CCNA1GSK3BCCNE1 | |
| SCHEMBL12953832 | 0.88 | GSK3B (0.70) | CDK2CCNA2CCNA1GSK3BCCNE1 | |
| SCHEMBL13305617 | 0.86 | CDK2 (0.52) | CDK2CCNA2CCNA1GSK3BCCNE1 | |
| SCHEMBL12952883 | 0.85 | CDK2 (0.76) | CDK2CCNA2CCNA1GSK3BCCNE1 | |
| SCHEMBL12953220 | 0.84 | CDK2 (0.84) | CDK2CCNA2CCNA1GSK3BCCNE1 | |
| SCHEMBL12953203 | 0.83 | CDK2 (0.80) | CDK2CCNA2CCNA1GSK3BCCNE1 | |
| SCHEMBL13116859 | 0.83 | GSK3B (0.77) | CDK2GSK3BCCNE1 | |
| SCHEMBL13305328 | 0.82 | CDK2 (0.70) | CDK2CCNA2CCNA1GSK3BCCNE1 | |
| SCHEMBL12953390 | 0.82 | CDK2 (0.70) | CDK2CCNA2CCNA1GSK3BCCNE1 | |
| SCHEMBL12953226 | 0.82 | CDK2 (0.75) | CDK2CCNA2CCNA1GSK3BCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| WO-2008130570-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130569-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20070281951-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-12-06 | — | — | US | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | CDK2 1/4885CCNA2 29/4885CCNA1 22/4885 |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885CCNA2 31/4885CCNA1 22/4885 |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885CCNA2 31/4885CCNA1 22/4885 |
| US-20070281951-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885CCNA2 32/4885CCNA1 24/4885 |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | CDK2 1/4885CCNA2 50/4885CCNA1 27/4885 |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885CCNA2 31/4885CCNA1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.